CCL27 and breast carcinoma: Based on our observation of ILC increase in the breast cancer models and the role of tumor ILC2 in invigorating anti-PD-1 treatment of aggressive cold pancreatic (PDAC) model (22), it seems that these cells could be valuable targets for enhancing other treatments, especially in immune deficiency cancers like breast cancer.